Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
IPO Year: 2013
Exchange: NASDAQ
Website: agios.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/10/2024 | $51.00 | Outperform | Raymond James |
| 9/27/2024 | $60.00 → $56.00 | Outperform → Market Perform | Leerink Partners |
| 2/8/2024 | Overweight | Cantor Fitzgerald | |
| 2/3/2023 | $41.00 | Overweight | Piper Sandler |
| 11/17/2022 | $17.00 → $32.00 | Sell → Neutral | Goldman |
| 7/27/2022 | $33.00 | Mkt Perform → Outperform | SVB Leerink |
| 3/7/2022 | $37.00 → $23.00 | Sell | Goldman Sachs |
| 3/3/2022 | $98.00 → $96.00 | Buy | HC Wainwright & Co. |
| 2/25/2022 | $61.00 → $67.00 | Outperform | RBC Capital |
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabo
– Topline Data from 52-week Phase 3 Study Expected in Late 2025 – CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that enrollment is complete for the Phase 3 RISE UP study. This global, double-blind, randomized, placebo-controlled trial is evaluating the efficacy and safety of mitapivat, an oral, small molecule PK activator, in sickle cell disease patients who are 16 years of age or older. Agios expects to report topline results from this 52-week Phase 3 study in late 2025. Sickle cell disease is an inherited, lifelong
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in pyr
CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's novel pyruvate kinase (PK) activator tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS). "Receiving orphan drug designation for tebapivat in MDS underscores the importance of bringing new oral treatment options to patients suffering from this rare disease," said Sarah Gheuens, M.D., Ph.D., chief medical officer and head R&D at Agios. "We aim to deliver the first ora
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to develop
– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – – Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress – CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the Company will receive a total of $1.1 billion in milestone payments following the U
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Who are Regularly Transfused – – PYRUKYND® (Mitapivat) Net Revenue of $8.6 Million in Q2; Cash, Cash Equivalents and Marketable Securities of $645.3 Million as of June 30, 2024 – CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWS
– ACTIVATE-KidsT is Agios' First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – – Prespecified Statistical Criterion for the Primary Endpoint in ACTIVATE-KidsT Was Not Met; Results Were Clinically Meaningful, with Observed Response Rates Higher for Mitapivat than Placebo for the Primary Endpoint of Transfusion Reduction Response and for the Secondary Endpoints of Transfusion-Free Response and Normal Hemoglobin Response – – Enrollment Completed for Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with PK Deficiency Who Are Not Regularly Transfused; Topline Data Expected in
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader i
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
Agios Pharmaceuticals (NASDAQ:AGIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.25, a high estimate
Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented detailed results from the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia in a plenary session (abstract #S104) at the European Hematology Association 2024 (EHA2024) Hybrid Congress, which is being held June 13-16, 2024, in Madrid, Spain. In a related poster presentation (abstract #P1529), the company presented additional data from the ENERGIZE study highlighting clinically meaningful improvements in health-related quality of life measures and patient-reported
https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C
JP Morgan analyst Tessa Romero reinstates Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and announces $46 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume A PUT TRADE BEARISH 07/19/24 $130.00 $620.0K 423 1.0K ISRG CALL SWEEP BEARISH 07/19/24 $345.00 $203.3
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study met primary endpoint. Several analysts raised their forecasts after the announcement. Verint Systems Inc. (NASDAQ:VRNT) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results and issued strong FY25 guidance. Novavax Inc (NASDAQ:NVAX) shares gained 21.54% in the last week after the U.S. Food and Drug Administration’s advisory committee voted to recommend updated vaccines for JN.1-line
Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $33 to $53.
RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $44 to $53.
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabo
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in pyr
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Who are Regularly Transfused – – PYRUKYND® (Mitapivat) Net Revenue of $8.6 Million in Q2; Cash, Cash Equivalents and Marketable Securities of $645.3 Million as of June 30, 2024 – CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWS
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader i
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., June 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented detailed results from the global Phase 3 ENERGIZE study of mi
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures of Reduction of Transfusion Burden Compared to Placebo – – ENERGIZE-T is the First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia – – As Part of Global Submission Strategy, U.S. Marketing Application for Mitapivat in Thalassemia Based on ENERGIZE and ENERGIZE-T Studies to be Submitted by End of 2024 – – Agios to Host Investor Webcast Event Today at 8:00 a.m. ET – C
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease – – Agios to Webcast Virtual Investor Event on June 16, 2024, at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that data from its programs will be presented at the European Hematology Association 2024 (
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia in January – – Phase 3 Readouts from Mitapivat RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceu
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in P
– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition – – Two Additional Phase 3 Readouts of Mitapivat Expected in 2024, with a Total of Four Phase 3 Readouts by the End of 2025 – – U.S. PYRUKYND® (mitapivat) Net Revenue of $7.1 Million in Q4; Cash, Cash Equivalents and Marketable Securities of $806.4 Million as of December 31, 2023 – CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fiel
Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity
Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling
Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform
Raymond James resumed coverage of Agios Pharma with a rating of Outperform and set a new price target of $51.00
Leerink Partners downgraded Agios Pharma from Outperform to Market Perform and set a new price target of $56.00 from $60.00 previously
Cantor Fitzgerald initiated coverage of Agios Pharma with a rating of Overweight
Piper Sandler initiated coverage of Agios Pharma with a rating of Overweight and set a new price target of $41.00
Goldman upgraded Agios Pharma from Sell to Neutral and set a new price target of $32.00 from $17.00 previously
SVB Leerink upgraded Agios Pharma from Mkt Perform to Outperform and set a new price target of $33.00
Goldman Sachs reiterated coverage of Agios Pharmaceuticals with a rating of Sell and set a new price target of $23.00 from $37.00 previously
HC Wainwright & Co. reiterated coverage of Agios Pharmaceuticals with a rating of Buy and set a new price target of $96.00 from $98.00 previously
RBC Capital reiterated coverage of Agios Pharmaceuticals with a rating of Outperform and set a new price target of $67.00 from $61.00 previously
10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
ARS - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
DEFA14A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and
– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Jeffrey Capello has been appointed to its board of directors. Agios also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. "Agios is dedicated to cultivating a diverse board that is focused on the company's long-term value creation for patients and shareholders. As such, we are thrilled to welcome Jeff, whose nearly 30-year track record of driving profitab
EMERYVILLE, Calif., April 12, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the appointment of Dr.Lewis Cantley, Dr. Hope Rugo, and Josep Tabernero to the company's Scientific Advisory Board (SAB). Totus has created the first biosearch technology that scans, maps, and decodes effective new drugs thousands of times faster than traditional drug discovery processes. To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023. Ms. Milanova will succeed Richa Poddar, who has been with Agios since 2016 and will continue to serve as the company's chief commercial officer until the end of the year. "Tsveta brings deep expertise in launching and commercializing medicines in rare disease and hematology, as well as international operations and global market access experience that will be a tremendous asset for Agios as we expan
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the appointment of Cecilia Jones to the role of chief financial officer, effective Sept. 26, 2022. Ms. Jones will replace Jonathan Biller, who served as the company's previous chief financial officer and head of corporate affairs and who resigned effective Sept. 16, 2022 in order to become chief legal officer of Vertex Pharmaceuticals. "With more than two decades of experience in financial leadership roles with leading biopharmaceutical companies, including most recently
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the appointments of Rahul Ballal, Ph.D., chief executive officer of Imara, and Cynthia Smith, former chief commercial officer of ZS Pharma, to its board of directors. "Agios is committed to assembling a top-notch, diverse board dedicated to realizing the company's long-term success and creating value for patients, shareholders, our team and all our stakeholders," said Brian Goff, chief executive officer of Agios. "Rahul and Cynthia are seasoned biopharmaceutical executives with cri
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. "We are thrilled to welcome John and Jen to the ProKidney Board. They each have a wealth of experience t
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the appointment of Richa Poddar to the role of chief commercial officer, effective Dec. 6, 2021. Ms. Poddar will replace Darrin Miles, who currently serves as the company's chief commercial officer and has been with Agios since 2015. Mr. Miles will depart the company to pursue a chief executive officer role at a private biotechnology company. "During her more than five-year tenure at Agios, Richa has played a significant leadership role in shaping our oncology portfolio and leading our oncology la